Article Details

Ocugen advances to high dose trial for Stargardt disease therapy - Investing.com

Retrieved on: 2024-06-22 03:40:17

Tags for this article:

Click the tags to see associated articles and topics

Ocugen advances to high dose trial for Stargardt disease therapy - Investing.com. View article details on hiswai:

Excerpt

In other recent news, Ocugen, Inc. has made significant strides in its gene and cell therapies and vaccines. The biotechnology company is set to ...

Article found on: www.investing.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up